- 1 **Title**: Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological
- 2 Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic
- 3 Profile
- 4
- 5 Author List: Vatsalya Vatsalya, MD, MS, PgD, MSc^{1,2*}, Fengyuan Li, PhD^{1,3}, Jane Frimodig,
- 6 PhD^{1,2}, Khushboo S. Gala, MD¹, Shweta Srivastava, PhD^{1,4}, Maiying Kong, PhD^{2,5}, Vijay A
- 7 Ramchandani, PhD⁶, Wenke Feng, PhD^{1,3,7,10}, Xiang Zhang, PhD^{3,7,8,9,10}, Craig J McClain,
- 8 MD^{1,2,3,7,10}
- 9

10 Affiliations:

- 11 ¹Department of Medicine, University of Louisville, Louisville, KY USA
- 12 ²Robley Rex VA Medical Center, Louisville, KY USA
- 13 ³University of Louisville Alcohol Research Center, Louisville, KY USA
- 14 ⁴Envirome Institute, University of Louisville, Louisville, KY USA
- 15 ⁵Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY USA
- 16 ⁶National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD USA
- 17 ⁷Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY USA
- 18 ⁸Department of Chemistry, University of Louisville, Louisville, KY USA
- ⁹Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville,
- 20 Louisville, KY USA
- 21 ¹⁰University of Louisville Hepatobiology & Toxicology COBRE, Louisville, KY USA
- 22

23 *Corresponding Author:

- 24 Vatsalya Vatsalya, MD, MS, PgD, MSc
- 25 Department of Medicine
- 26 University of Louisville School of Medicine
- 27 505 S. Hancock St., CTR Room 514A
- 28 Louisville KY 40202
- 29 Landline: 502-852-8928, Fax: 502-852-8927
- 30 Cell: 502-488-0446; Email: v0vats01@louisville.edu
- 31
- 32 Running Head: Thiamine Treatment for COVID-19: Th17 Immune Storm and Neurological
- 33 Symptoms.
- 34
- 35 Author contribution: VV is the project PI and designed the study. VV and JF participated in the
- 36 clinical sampling and clinical data analyses. FL performed *in vitro*, and JF performed plasma
- 37 testing. FL, JF, and VV participated in the overall laboratory analyses. MK and VV developed the
- dosing range. VV, CJM and VAR developed the pharmacokinetic profile. VV, FL, SS, and JF
- 39 interpreted the results. VV, FL, JF, SS, and KSG wrote the manuscript. CJM, MK, WF, XZ, and VAR
- 40 critically reviewed the manuscript and contributed scientifically. All authors have approved the
- 41 submission version of this manuscript.
- 42
- 43 **Conflicts of Interest**: All authors declare no conflict of interests.
- 44

45 **Proprietorship:** This article is a work of the University of Louisville Alcohol Research Center and 46 National Institutes of Health. This manuscript is in the public domain in the USA. Email address 47 for the readers to contact the author to obtain the data: v0vats01@louisville.edu. 48 49 **Project/Grant Support:** Study was supported by NIH: NIH-OD-OHSRP-12176 (VV), 50 R15CA170091-01A1 (MK), ZIA AA000466 (VAR), R01AA023190 (WF), P50AA024337-8301 and 51 P20GM113226-6169 (XZ), and P50AA024337, P20GM113226, U01AA026936, U01AA0279880, 52 R01AA023681 (CJM). The content is solely the responsibility of the authors and does not 53 necessarily represent the official views of the National Institutes of Health. 54 55 Acknowledgments: We thank research/clinical staff of the University of Louisville for their 56 support. We thank Ms. Marion McClain for editing this manuscript. 57 58 Ethics approval and consent to participate: Study was approved by the sites' Institutional 59 Review Boards (Ethics committees). All patients included in this study consented to participate 60 before the beginning of the study. 61 62 Availability of data and materials: The datasets analyzed during the current study are available 63 from the corresponding author by request. 64 65 **Disclosure:** This article is not published nor is under consideration for publication elsewhere at 66 the time of submission. 67 68 Abbreviations: COVID-19: Coronavirus Disease-19, IL-17: Interleukin 17, IL-22: Interleukin 22, 69 Disease Controls: (DC), HV: Healthy Volunteers. 70 71 Trial registration: ClinicalTrials.gov identifier - NCT# 01809132 and 00106106. 72 73 Reprint requests: Vatsalya Vatsalya MD, PgD, MSc, MS, Department of Medicine, University of 74 Louisville School of Medicine, 505 S. Hancock St., CTR Room 514A, Louisville KY 40202 USA. Tel.: 75 502-852-8928. Fax: 502-852-8927. E-mail: v0vats01@louisville.edu. 76 77 Manuscript metadata: Word Count in manuscript draft: 3383 manuscript words. 78 79 Tables and Figures: 1 Table, 4 Figures, and 2 Suppl. Tables. 80 Number of References: 110. 81 82 83 84

85 Abstract

86 Introduction

87 Emerging infectious diseases, especially the coronavirus disease identified in 2019 88 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17 89 proinflammatory immune storm. This enhanced immune response plays a major role in 90 mortality and morbidity, including neurological symptoms. We hypothesized that countering 91 the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell 92 proinflammatory response. We used an *in vitro* study and corroborated those results in disease 93 controls (DC). We developed an effective dose range and model for key pharmacokinetic 94 measures with the potential of targeting the cytokine storm and neurological symptoms of 95 COVID-19. 96 Study Participants and Methods 97 We investigated the effect of a three-week 200 mg dose of thiamine in lowering the

98 Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients; 99 and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To 100 further investigate, we performed an *in vitro* study evaluating the effectiveness of thiamine 101 treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line 102 (RAW264.7) treated with ethanol. In this *in vitro* study, 100 mg/day equivalent (0.01 μ g/ml) 103 thiamine was used. Based on recent publications, we compared the results of the IL-17 104 response from our clinical and *in vitro* study to those found in other proinflammatory disease 105 conditions (metabolic conditions, septic shock, viral infections and COVID-19), including 106 symptoms, and dose ranges of effective and safe administration of thiamine. We developed a 107 dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-

108 19 to alleviate the effects of the cytokine storm and neurological symptoms.

109 <u>Results</u>

110 The DC group showed significantly elevated proinflammatory cytokines compared to 111 HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17 112 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an in 113 vitro macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in 114 attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only 115 treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective 116 and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that 117 several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in 118 other viral infections and neuroinflammatory states that may also respond to thiamine 119 treatment. 120 Discussion 121 The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by 122 thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating 123 the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed 124 in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in 125 severe COVID-19 patients could identify its precise anti-inflammatory role.

126

127 Key words: COVID-19, IL-17, IL-22, Cytokine storm, Pandemic

128

129 Introduction

130	Viral diseases and wide-spread outbreaks have adverse health-related consequences
131	worldwide. Emerging infectious diseases (EID) include viral pathogens that have shown higher
132	incidence of human infection in the past several decades and raise concerns regarding
133	increased ongoing/future prevalence ¹ . Coronavirus is recognized as an EID that has become a
134	challenging and aggressive infection with high morbidity and mortality in humans ² . SARS-CoV-2
135	(severe acute respiratory syndrome coronavirus 2; causes coronavirus disease [COVID-19]) was
136	identified in 2019, has become a pandemic, and is a priority healthcare concern in the year
137	2020 ³ .
138	In viral infections, tissue inflammation is driven by multiple proinflammatory and
139	immunoregulatory signals ^{4,5} . The pathological progression of COVID-19 has multiple clinical
140	stages and may present with the cytokine storm syndrome ⁶ and immunosuppression ⁷ .
141	Interleukin-17 (IL-17) is a cytokine ⁸ that is often involved in a proinflammatory response in the
142	cytokine storm of viral infections ⁹⁻¹¹ . It can also promote respiratory viral infections ¹² , tissue
143	pathology ¹³⁻¹⁵ , and neurological manifestations ¹⁶ . Th17 cells also produce Interleukin-22 (IL-
144	22), which plays a protective/anti-inflammatory role, and it is dysregulated in several
145	proinflammatory conditions ¹⁷ . Thus, a therapy that could alleviate the Th17 mediated pro-
146	inflammatory response ¹⁸ might be effective in attenuating the cytokine storm observed in
147	COVID-19 patients.
148	Thiamine, a vitamin and dietary supplement, ¹⁹ has anti-oxidant properties ^{19,20} . High
149	levels of cytokines (for example, IL-1 β and IL-6) may occur in thiamine deficient subjects and

150 can be associated with oxidative stress and inflammation ^{21,22}. Importantly, thiamine

151	administration could inhibit production of these cytokines, increase anti-inflammatory activity
152	^{23,24} , and potentially alleviate neuroinflammatory symptoms of viral origin ^{25,26} .
153	We tested the efficacy of a three-week thiamine treatment in modulating the Th17
154	proinflammatory response in a human disease control model of conditions associated with
155	inflammation. To validate the effectiveness of thiamine in treating the proinflammatory
156	response from the human study, we conducted an in vitro experiment to test the effects of
157	thiamine treatment in alleviating ethanol mediated immune dysregulation in a mouse
158	macrophage cell line, RAW264.7. We investigated the Th17 cells proinflammatory cytokine
159	response (namely IL-17) in both healthy controls and individuals with high inflammatory
160	response. This was done to estimate the effects of various doses of thiamine that have shown
161	efficacy in alleviating the Th17 associated cytokine response. We assessed the
162	pharmacokinetics of the oral thiamine dosing. Lastly, we also examined the neurological
163	symptoms of COVID-19 that could possibly be treated with thiamine.
164	
165	Study Participants and Methods
166	Study Participants
167	This investigation was approved under two large clinical investigations that were
168	conducted at the University of Louisville (NCT#01809132, HV cohort), and the National Institute
169	on Alcohol Abuse and Alcoholism (NIAAA) (NCT#00106106, DC cohort) at the National Institutes
170	of Health (NIH), Bethesda MD. The studies were approved by the NIH Institutional Review
171	Board (IRB) committee and the UofL IRB (IRB # 12.0427). All DC (disease controls as termed in
172	this study, who were alcohol use disorder [AUD]) patients received acamprosate (or placebo) as

173 part of a larger addiction intervention investigation. All of these patients also received thiamine 174 as part of the medical management, which is the primary aim of this study. Sixteen age- and sex-matched male and female alcohol use disorder (AUD) patients (Termed as disease controls 175 176 [DC] in this investigation) between 21-65 yrs. of age with both present and past heavy drinking 177 profile participated as the DC, who were diagnosed with AUD based on DSM-IV TR criteria. 178 They received daily doses of open label thiamine (100 mg twice daily = 200 mg per day) ²⁷ for 3-179 weeks after completion of the consenting process. DC patients also received standard of care 180 inpatient medical management, including counseling. Detailed information on subject 181 recruitment and management can be obtained from several of our previous publications ²⁸⁻³¹. 182 We also included eight healthy controls in this study for comparison with DC. Demographic data 183 were collected from all the participants. Baseline (HV and DC) and post-treatment (DC only) 184 blood samples (after the completion of 3-weeks of thiamine dosing) were collected, processed 185 (for plasma extraction) and frozen at -80°C. They were subsequently thawed and assayed. Laboratory Assays and Therapeutic Model on Th17 Inflammation Axis 186 187 (1) Cytokine assays 188 Plasma levels of proinflammatory cytokines, IL-1 β , IL-6, and IL-10 were obtained by 189 multianalyte chemiluminescent detection using Multiplex kits (Millipore, Billerica, MA) on the 190 Luminex platform (Luminex, Austin, TX), according to manufacturers' instructions. 191 (2) Analysis of IL-17 and IL-22 in a set of AUD patients for designing proof-of-concept 192 experimental model 193 We performed analyses for IL-17 and IL-22 on human plasma samples to estimate the 194 Th17 inflammatory response, with the goal of developing an *in vitro* mechanistic experimental

195	model to test the efficacy of thiamine. The plasma levels of IL-17 and IL-22 in eight healthy
196	volunteers were also included in this study for comparison. IL-17 and IL-22 were detected in
197	plasma using Human IL-17A (now called IL-17) High Sensitivity ELISA Kits (BMS2017HS,
198	Invitrogen) and Human IL-22 ELISA Kits (BMS2047, Invitrogen) per the manufacturer's
199	instructions. Results were read on a Spectra Max Plus 384 plate reader and modeled using their
200	SoftMax Pro software (Molecular Devices, San Jose, CA).
201	(3) <u>Cell culture</u>
202	RAW 264.7 cells (mouse macrophage cell line) were cultured in Dulbecco's modified
203	Eagle's medium (DMEM, Invitrogen), supplemented with 10% fetal bovine serum (FBS) and 1%
204	penicillin/streptomycin. Cells were seeded in a 24-well culture plate and maintained at 37 °C in
205	a 5% CO $_{2}$ incubator for 3 days. The 0.02 $\mu g/mL$ treatment dose was equivalent to the 200
206	mg/day thiamine dose (approximate blood AUC = 204 nmol/L 32) given to the patients. Cells
207	were then treated with thiamine (Vit B1 $[V_{B1}]$ as shown in the Figure 2) at a concentration of
208	(0.01 μg/mL) for 2 hours (in a preventive paradigm), followed by 80 mM ethanol treatment for

209 22 hours, for a total of 24 hours of treatment to determine the minimum effective level of

210 thiamine to reduce the Th17 response. Cells were then washed with PBS and collected with

211 Trizol reagent for the isolation of RNA. RNA samples were reverse transcribed to cDNA and

used for qRT PCR analysis of cytokine expression (IL-17, IL-22). Cell viability was not affected by

213 thiamine or EtOH treatment at the doses used in the experiments.

214 (4) RNA isolation and real-time RT-PCR

215 Total RNA was extracted from the cells using Trizol reagent (500 μl/well) according to

216 manufacturer's instruction (Life Technologies, Carlsbad, CA) and reverse-transcribed using

cDNA Supermix (QuantaBio, Beverly, MA). Quantitative real-time PCR was performed on an ABI
7500 real-time PCR thermocycler and SYBR green PCR Master Mix (Applied Biosystems, Foster
City, CA) was used for quantitative real-time PCR analysis. The relative quantities of target
transcripts were calculated from duplicate samples after normalization of the data against the
housekeeping gene, mouse 18S. Relative mRNA expression was calculated using comparative Ct

222 method. The following primer pairs were used:

Gene name	Forward sequence 5'->3'	Reverse sequence 5'->3'
ms /L-17	ATCCCTCAAAGCTCAGCGTGTC	GGGTCTTCATTGCGGTGGAGAG
ms /L-22	GTCAACCGCACCTTTATGCT	CATGTAGGGCTGGAACCTGT
ms 18S	GTAACCCGTTGAACCCCATT	CCATCCAATCGGTAGTAGCG

223

224 Development of the Pharmacokinetic Model for Dose Titration of Thiamine

225 We used dosing guidelines for thiamine as mentioned at the Medline Plus

226 (https://medlineplus.gov/druginfo/natural/965.html#Safety, last reviewed as of August 5,

227 2020), and from peer reviewed publications from PubMed (<u>https://pubmed.ncbi.nlm.nih.gov/</u>;

- 228 [searched and collected until August 5, 2020]). We used available dosing guidelines from
- 229 Medline Plus for healthy individuals both for dietary supplementation and vitamin deficiency
- 230 status. We also reviewed and incorporated thiamine dose levels (lower and higher range) from
- other disease conditions; namely metabolic conditions ^{33,34}, septic shock ^{35,36}, viral diseases ³⁷⁻³⁹
- and Leigh's disease⁴⁰ (Medline Plus: Thiamine). We also included the recorded thiamine dose
- 233 levels from the DC group (AUD with Wernicke Korsakoff Syndrome, WKS⁴¹; from our clinical
- study) as one of the pro-inflammatory conditions.

235	We compared the reference range of levels of the Th17 cytokine (IL-17) response in
236	disease/health conditions in humans as published in the recent findings concerning COVID-19's
237	cytokine storm data ⁴²⁻⁴⁴ . A Th17 proinflammatory response for the potential range of IL-17
238	levels was also developed for healthy volunteers (HV, from our study cohort), metabolic
239	conditions ^{45,46} , DC (or alcohol use disorder patients from our study cohort), septic shock ^{47,48} ,
240	and viral infections ^{12,49} . IL-17 data on severe COVID-19 patients (as mentioned above) were
241	collected from the recently peer-reviewed published articles found in PubMed (searched until
242	August 5, 2020). Doses administered to our DC study cohort, and data from healthy individuals
243	(HV) were also used in the development of the dose profile. All these data were incorporated in
244	the predictive regression model for identifying a tentative effective dose range of thiamine
245	(Figure 3).
246	The pharmacokinetic response of thiamine was calculated at both the low and high ends
2.47	

of the dose range described above. The area under the curve and maximum concentration 247 248 (C_{max}) were established for both blood and plasma for a 10-hour trajectory (Figure 4) using the 249 indices of thiamine's *in vivo* blood pharmacokinetics³². For the derived 79 mg thiamine dosing 250 (low end), the slopes used to identify AUC in blood were 2.14, and 1.76 in plasma . For the 474 251 mg thiamine dosing (upper end), the slope used to derive AUC in blood was 1.02, while in 252 plasma it was 1.09. Similarly, for the 79 mg thiamine dosing, the slope used to derive C_{max} in 253 blood was 0.40, and in plasma it was 0.39. For the 474 mg thiamine dose, the slope used to 254 derive AUC in blood was 0.14, and in plasma it was 0.18.

255 Statistical Analysis

256 Data are expressed as Mean ± standard deviation (M±SD) in Table 1 as well as in Figures 257 1 and 2. Two-sided Student's t-test was used to examine the difference between disease 258 controls and healthy volunteers at baseline (see Suppl. Table 1 and Fig. 1), and two-sided 259 Student's paired t-test was used to examine the changes at baseline versus 3 weeks for disease 260 controls (Figure 1). 261 Post-hoc one-sided t-tests were performed for the IL-17 and IL-22 mRNA expression 262 analyses for the RAW 264.7 cells testing (Figure 2). A pharmacokinetic model for anticipated 263 therapeutic dosing range of thiamine based on IL-17 ranges in different inflammatory 264 conditions was constructed using predictive regression computation (Figure 3). Factorial 265 between-group ANOVA was used to evaluate demographic and cytokine profiles (Table 1). 266 Statistical significance was established at p<0.05. SPSS 26.0 (IBM Chicago, IL) and Microsoft 267 Excel 365 (MS Corp, Redmond WA), statistical software R (https://www.r-project.org/), and 268 Prism GraphPad (GraphPad Software, San Diego CA) were used for statistical analysis, data 269 computation, and plotting the figures. 270 Neurological Assessments 271 We conducted a review on the neurological presentation in COVID-19 and other 272 relevant viral occurrences of encephalitis (Table 1). We identified and tabulated the 273 neurological symptoms of COVID-19 and viral encephalitis from the recently published findings. 274 We also described the neurological symptoms, that are generally treated effectively with 275 thiamine (Table 1). We used PubMed and Medline Plus for disease references (searched until

276 August 5, 2020).

277

278 Results

279 Demographics and Candidate Proinflammatory Cytokine Profile

280 DC group individuals in this study had significantly higher age than the healthy controls

281 (HV) (Suppl Table 1). However, there was no significant difference in the mean BMIs between

the two groups, and the sex-distribution was also similar between the two groups. Both IL-6 (~6

fold) and IL-1β (~3 fold) cytokines were significantly higher in the DC group (AUD patients)

compared to the healthy controls/volunteers (HV) group. IL-10 was also numerically higher in

the DC group.

286

287 Clinical Findings on the Immune Response of Th17 derived IL-17 and IL-22 Axis Response, and
288 Thiamine Efficacy and Safety

289 To develop a model for thiamine effects on inflammation, we assessed IL-17 and IL-22 290 cytokine expression (showing proinflammatory and anti-inflammatory effects, respectively). 291 Both cytokines are produced by the Th17 cells ⁵⁰. IL-17 concentrations were below the level of 292 detection in the HV group, but were elevated in the DC group. An approximate four-fold 293 decrease was observed in the IL-17 concentration levels (0.09 pg/mL to 0.023 pg/mL) with a 294 treatment dose of 200 mg thiamine daily (Estimated AUC = 204 nmol/L x hour approximately in 295 the 10-hr. window) by the end of week 3. IL-22 was significantly decreased in DC group 296 compared to healthy volunteers and thiamine therapy did not significantly improve levels in 297 treated DC group individuals. No patients reported any kind of drug related adverse events; 298 therefore, the safety profile of thiamine administration was excellent at 200 mg daily in this 299 small pilot group.

300

301 Experimental Model for Treatment Efficacy of Thiamine on IL-17 and IL-22 Activity

302	Using these clinical findings of the treatment efficacy of thiamine, we designed an in
303	vitro experiment using mouse macrophage RAW264.7 cells to validate the effects of thiamine
304	on alcohol-induced IL-17 and IL-22 expression. The results showed that a low dose of thiamine
305	(V_{B1}) decreased IL-17 expression in the absence (by 20% approximately) and/or presence of
306	alcohol treatment (by 25% roughly) (Figure 2a). Importantly, IL-22 expression was upregulated
307	by thiamine in both the control and ethanol-treated cells. This response in IL-22 expression was
308	moderately reduced by alcohol but rescued by the thiamine (V_{B1}) treatment (Figure 2b). Half of
309	the treatment dose (0.02 μ g/mL) that was found to be effective in humans was beneficial as a
310	preventative dose (0.01 μ g/mL) of thiamine in this <i>in vitro</i> model.
311	

312 IL-17 Dependent Dose and Pharmacokinetic Model of Thiamine

313 An IL-17 response dependent dose and pharmacokinetic model of thiamine 314 administration was developed, based on responses from the pro-inflammatory disease cohorts 315 and the corresponding thiamine dosing (controlled for by the corresponding values in healthy volunteers, as a point of reference). This model supported a tentative range of thiamine dosing 316 317 for COVID-19 (Figures 3A and 3B), since the IL-17 levels are much higher in COVID-19 than in 318 the reports from many other proinflammatory disease conditions. Using regression analysis, a 319 range of 79 mg/day (lower end of dose range) - 474 mg/day (higher end of dose range) for 320 thiamine administration was found to correspond to a range of 15-40 ng/mL level of IL-17 used 321 in vitro.

322	The pharmacokinetic parameters were: Area Under the Curve (AUC), and Maximum (or			
323	peak) Concentration of a drug (C_{max}). These gave a very close estimation of the specific oral			
324	thiamine dose (Figure 4). As expected, plasma values were higher for both AUC and C_{max} at			
325	higher doses and were lower at lower doses (Suppl Table 2).			
326				
327	Assessment of Neurological Presentation of COVID-19, Viral Encephalitis and Therapeutic			
328	Efficacy of Thiamine Administration			
329	We tabulated the neurological symptoms from the recently published findings on			
330	COVID-19 (Table 1). Severely ill COVID-19 patients presented with various neurologic symptoms			
331	that could be grouped together as: acute cerebrovascular disease; altered mental status; and			
332	musculoskeletal symptoms ⁵¹ . We also included the neurological presentation commonly			
333	observed in viral encephalitis of non-COVID-19 origin, grouped corresponding to the			
334	presentation of the symptoms of COVID-19.			
335	Lastly, we also tabulated the neurological symptoms that are commonly treated with			
336	thiamine. Several neurological symptoms of COVID-19 and viral encephalitis corresponded well			
337	with the neurological spectrum that is known to be managed effectively with thiamine.			
338				
339	Discussion			
340	We evaluated individuals with significantly altered IL-17 and IL-22 responses associated			
341	with Th17 cells and found a significant role for a 3-week 200 mg/daily thiamine treatment			
342	regimen in improving the Th17 response in the AUD disease control patient cohort whose			
343	members exhibited a high pro-inflammatory status at baseline. SARS CoV-2 viral challenge			

344	causes induction of IL-6 leading to altered Th17 responses ⁵² . IL-17 synthesized by Th17 cells
345	can markedly stimulate neutrophil chemotaxis and may lead to a skewed Th2 immune response
346	^{53,54} . Results from our AUD control group show the increases in candidate proinflammatory (IL-
347	1β and IL-17), and anti-inflammatory (IL-6, IL-10 and IL-22) cytokines. Changes in IL-17 and IL-22
348	with alcohol abuse (pro-inflammatory), and thiamine as an anti-inflammatory therapy in our
349	experiment provided potential proof of concept. IL-1 β is a key cytokine initiating Th17 cells to
350	synthesize IL-17 ⁵⁵ , whereas IL-10 suppresses Th17 proinflammatory cytokine production ⁵⁶ .
351	High IL-6 levels also are associated with Th17 cell proinflammatory activity ⁵² . Thus, under
352	inflammatory conditions, there is a complex interaction of proinflammatory/anti-inflammatory
353	responses from Th17 cells. An intervention or prevention that could attenuate the Th17
354	proinflammatory activity could help ameliorate the consequences of a cytokine storm.
355	Thiamine deficiency has been reported to promote a proinflammatory response in Th1
356	and Th17 cells ⁵⁷ . To examine the role of thiamine in treating inflammation, <i>in vitro</i> testing was
357	used to mechanistically examine the clinical outcomes. Our in vitro model showed that
358	thiamine could effectively lower IL-17 and increase IL-22 mRNA expression in macrophages.
359	Both our clinical data, and the <i>in vitro</i> studies suggest that thiamine could play a potential role
360	in attenuating the cytokine storm in patients who have a strong proinflammatory response.
361	A study using a mouse model showed that IL-17 augments respiratory syncytial virus
362	(RSV)-induced lung inflammation ⁵⁸ . In that study, immunodepletion of IL-17 before viral
363	infection resulted in diminished RSV-driven mucous cell hyperplasia and airspace enlargement,
364	suggesting IL-17 as a potential therapeutic target. Proinflammatory IL-17 production could also
365	initiate pulmonary eosinophilic response, by promoting proliferation of eosinophils in the bone

marrow, followed by recruitment and extravasation into the lungs ⁵⁹. These recent findings
 suggest that suppression of IL-17 may be vital to managing viral infections, including COVID-19
 and their harmful consequences.

We derived an effective dose range of thiamine that could be administered for 369 370 alleviating the Th17 cell proinflammatory response by using the IL-17 concentrations that we 371 obtained from our AUD patients (termed as DC), levels found in the literature, and levels in the 372 healthy control (HV) group. Thiamine has been administered as a treatment in other viral infections ^{60,61}, and has proven effective for some inflammatory conditions and symptoms ^{62,63}. 373 374 A well-structured treatment profile of thiamine based on the results of proof of concept in vitro 375 experiments, and analyses of proinflammatory response-relevant disease conditions support 376 the potential efficacy of thiamine in ameliorating the proinflammatory Th17 response in severe 377 COVID-19 patients. Use of preventive as well as interventional dosages show potential in the 378 management of COVID-19. Thiamine C_{trough} is reached generally in 10-12 hours; thus, the total 379 dose prescribed can be divided into two doses per day. This may lead to fewer AEs or other side effects. 380

One recent report identified that 36.4% of the COVID-19 diagnosed patients have neurologic symptoms, and this proportion was higher (45.5%) among those COVID-19 patients with more severe symptoms ⁵¹. Patients with other viral diseases have also shown clinical symptoms of beriberi ⁶⁴, or Wernicke-Korsakoff syndrome (autopsies of 380 people with AIDS showed Wernicke's encephalopathy in 10% of the cases) ⁶⁵, and these conditions are associated with thiamine deficiency. It is possible that patients with viral infection could have an increased risk of thiamine deficiency, but this information has remained largely unexplained in viral diseases ⁶⁶, including COVID-19. A potential reason could be that a deficiency in thiamine could be related to the thiamine transport protein, which can have a general preference for multiple membrane transport molecules which can function as receptors for candidate viruses ⁶⁷. The Th17 proinflammatory response has also been reported in the experimental encephalomyelitis model ⁵⁷. Thus, thiamine could be a therapeutic agent to alleviate neurological symptoms of COVID-19.

394 Adverse effects (AE) of thiamine are minimal and generally mild. Possible AEs include 395 nausea, diarrhea, and abdominal pain. Rarely, individuals also suffer serious allergic reactions. 396 There is no reported drug related symptoms at the 200 mg thiamine dose used in our study, 397 and there are no reported AEs. A landmark pharmacokinetic study utilizing a 1500 mg maximum oral dose of thiamine in healthy subjects showed rapid absorption ³². Moreover, 398 399 4000 mg thiamine administration showed no to mild AEs when used in children (Leigh's 400 disease). Thus, higher doses of thiamine for treatment of COVID-19's cytokine storm could be 401 considered a safe therapy.

402 Our study has several limitations. This is a small study. However, both clinical and in 403 vitro evidence collectively support the potential of thiamine as a therapeutic agent in 404 attenuating the Th17 proinflammatory response. We did not test the in vitro/in vivo efficacy of 405 thiamine in the treatment of COVID-19 or its derivative stimulated Th17 proinflammatory 406 response directly. We anticipate conducting such in vitro experiments for COVID-19 as a 407 continuation of this project. Moreover, plasma thiamine levels have not been assessed in COVID-19. Our study did not have sufficiently large numbers of males and females; thus, 408 409 identifying sex-differences was not within the scope of this study.

- 410 In summary, Thiamine has been approved by the Food and Drug Administration (FDA) of
- 411 the USA as a prescription product and is considered very safe even at higher doses since it is
- 412 water soluble and can be excreted via urine, if in excess ⁶⁸. Given its robust safety record, we
- 413 suggest that thiamine should be considered for COVID-19 treatment studies.
- 414
- 415 Tables
- 416 Table 1. Neurological symptoms in COVID-19, Viral Encephalitis (Grouped/assorted by the
- 417 neurological spectrum observed in COVID-19), showing their proximity in presentation.
- 418 Therapeutic effects of thiamine on the corresponding neurological symptoms of pro-
- 419 inflammatory origin that are also observed in viral infection.

COVID-19	Viral Encephalitis	Therapeutic Effects of Thiamine on WKS and other Neurological Conditions	Corresponding Clinical Indications
	Central Nervous Syste	m (CNS) Symptoms	
Altered Mental Status ^{51,69}	Disorientation ⁷⁰	Mental Confusion ^{71,72} , Impaired Memory ⁷¹ ,	Confusion: WKS Classic Triad
Epiphora, Conjunctival Congestion, or Chemosis (swollen conjunctiva) ⁷³ ; Ophthalmoplegia ⁷⁴ (part of MFS)	Ocular Paralysis ⁷⁵ , internuclear Ophthalmoplegia ⁷⁶⁻⁷⁸	Ophthalmoplegia (nystagmus) ⁷¹	Ocular: WKS Classic Triad
Ataxia ^{51,79} (part of MFS): Movement ⁷⁴ , and Unstable Walking ⁶⁹ ,	Ataxia ^{26,70}	Gait Ataxia ⁷¹	Ataxia: WKS Classic Triad
Fatigue ⁶⁹ , Dizziness and Languidness ^{51,69} , Malaise ⁶⁹ , Headache ^{51,69}	Weakness and Somnolence ²⁶ , Nausea ⁸⁰	Lack of Energy/Fatigue, Drowsiness, Fainting, Sluggishness ⁷¹ ; Apathy ⁷¹	Generalized features
Cerebral Hemorrhage ⁶⁹ , Cerebral Infarction ⁶⁹	Cerebral Hemorrhage ⁸¹ , Intracranial Pressure ⁸²	Hemorrhages ⁷¹	Cerebrovascular

Epilepsy ^{51,83}	Epilepsy ^{84,85}	Seizures (Alcohol Withdrawal) ⁸⁶	Pathophysiological
Encephalomyelitis:		Demyelination ⁹¹ within	
Demyelinating 69,87,	Encephalomyelitis ^{89,90}	Periventricular	Pathomorphological
Disseminated ⁸⁸		Structures	
	Peripheral Nervous Syst	em (PNS) Symptoms	
Hypogeusia (low ability to	Hypogeusia (low	Efficacy Not Well-	Concern
taste) ^{51,92-94}	ability to taste) ⁹⁵	Established	Sensory
Hyposmia (low ability to	Hyposmia (low ability	Efficacy Not Well-	Soncorry
smell) ^{51,93,94,96}	to smell) ⁹⁵	Established	Sensory
Nerve pain ⁹⁷ (also in the	Neuralgia ^{98,99}	Neuralgia ^{100,101}	Neuralgia
head and face region ⁵¹)	i i cui digid		i ve u u giu
		Racing of Heart (faster	
Tachycardia ^{102,103}	Tachycardia ^{70,104}	heartbeat), Low Blood	Cardiovascular
Tactiveardia		pressure ⁷¹ ,	
		Tachycardia ⁷¹	
Musculoskeletal Symptoms			
Mussle Injuny ^{51,105}	Ducarthria ²⁶ Norue	Motor impairment ¹⁰⁷ ,	
Aroflovia (part of MES) ⁷⁴	Impairment ¹⁰⁶	Motor Cortex	Motor
Arenexia (part or MFS)		Excitability ¹⁰⁸	

420 Footnote – WKS: Wernicke Korsakoff Syndrome ¹⁰⁹; MFS: Miller Fisher Syndrome ¹¹⁰.

421

422 Figure Legends

423 Figure 1: Efficacy of thiamine treatment on Th17 cell derived response for IL-17, and IL-22

424 cytokines. Levels of IL-17 and IL-22 in healthy volunteers (HV) at baseline; and Disease Controls

425 (DC or [alcohol use disorder, AUD]) patients exhibiting a proinflammatory response (n=16) at

- 426 baseline; and anti-inflammatory normalization of cytokines tested after the completion of
- 427 three-week (W3) thiamine treatment. A drop in IL-17 coupled with a mild increase in IL-22 at
- 428 W3 was observed compared to the baseline levels. BL: baseline, W3: three-week of thiamine
- 429 treatment. Data are presented as M±SD. Statistical significance was set as p < 0.05.

430

431	Figure 2: mRNA expression of IL-17 and IL-22 in an <i>in vitro</i> model of the mouse macrophage cell
432	line using a potent proinflammatory agent (alcohol), and preventative administration of
433	thiamine. Fig. 2a: Significant lowering was observed in IL-17 mRNA expression in "EtOH + V_{B1} "
434	(Bar 4) group compared to the alcohol-treated group (Bar 3). Fig. 2b: Significant elevation was
435	observed in IL-22 mRNA expression in "EtOH + V_{B1} " (Bar 4) group compared to the alcohol-
436	treated group (Bar 3). Controls (both Fig. 2a and 2b) show normal anti-inflammatory effects of
437	thiamine on IL-17 and IL-22 response with thiamine administration. Ctrl: Non-treated controls.
438	V_{B1} 0.01 ug/ml. EtOH: alcohol treated. V_{B1} +E: thiamine and alcohol treated. Data are presented
439	as M±SD. Statistical significance was set as p < 0.05.
440	
441	Figure 3. PRIMARY: A dose titration by disease and proinflammatory Th17 status model of
442	thiamine administration with parallel representation of Th17 proinflammatory response in
443	various groups including healthy volunteers and disease groups with pro-inflammatory
444	response. Fig. 3A: Linear regression model is predictive for the relation between the low dose
445	thiamine (Vit B1) range versus low IL-17 ranges based on known observed pairs from different
446	patients; lower range of vit B1 dose (79 mg/daily) corresponding to lower range of IL-17 (15
447	ng/ml) in the COVID-19 patients. Dark grey shade depicts higher IL-17 response and lighter grey
448	shade shows lower IL-17 response in various proinflammatory conditions. Fig. 3B: Linear
449	regression shows the predictive model for the relation between a higher range of Vit B1 dose
450	versus a higher range of IL-17 levels, derived from the known observed pairs from different
451	patients; higher range of Vit B1 dose (474 mg/daily) corresponding to higher range of IL-17 (40
452	ng/ml) reported in COVID-19 patients. High Range Thiamine Dose: Left Y-axis (primary). Low

453	Range Thiamine Dose Lov	v Range II -17 levels	and High range II -1	7 levels: Right Y-axis
455	hange mannie Duse, Lui	v nalige it-t/ ievels,	, and ingritalige it-1	. ievels. Night Faxis

- 454 (Secondary).
- 455
- 456 Figure. 4. Pharmacokinetics parameters of oral thiamine over 10 hr. (Projected) in whole blood
- 457 and plasma. Fig. 4a: Predicted course of Area Under the Curve (AUC) for low values (79 mg/day)
- 458 and high values (474 mg/day) of the range of oral thiamine dose in blood and plasma over the
- 459 10 hours. Fig. 4b: Predicted maximum concentration of low values (79 mg/day) and high values
- 460 (474 mg/day) of the range of oral thiamine dose in blood and plasma over the first 10 hours.
- 461 Errors bars show a 5% variability in the pharmacokinetic measures at each dose.

462

463 References

- 464 1. Hassell JM, Begon M, Ward MJ, Fèvre EM. Urbanization and disease emergence:
- 465 dynamics at the wildlife–livestock–human interface. *Trends in ecology & evolution*.
 466 2017;32(1):55-67.
- 467 2. Poon LL, Peiris M. Emergence of a novel human coronavirus threatening human health.
 468 *Nature medicine*. 2020;26(3):317-319.
- 469 3. HuiDS IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV
 470 epidemicthreatof novel coronaviruses to global health: the latest 2019 novel
- 471 coronavirus outbreak in Wuhan, China. *Int J Infect Dis.* 2020;91:264-266.
- 472 4. Glass WG, Rosenberg HF, Murphy PM. Chemokine regulation of inflammation during
 473 acute viral infection. *Current opinion in allergy and clinical immunology*. 2003;3(6):467474 473.
- 475 5. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, 476 inflammation and intervention. *Nature Reviews Immunology*. 2020:1-12.
- 477 6. Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. *The Journal of clinical investigation*.
 478 2020;130(5).
- 479 7. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19:
 480 consider cytokine storm syndromes and immunosuppression. *The Lancet.*481 2020;395(10229):1033-1034.

482 8. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. 483 Journal of leukocyte biology. 2002;71(1):1-8. 484 9. Reed M, Morris SH, Owczarczyk AB, Lukacs NW. Deficiency of autophagy protein Map1-485 LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER 486 stress-associated IL-1. Mucosal immunology. 2015;8(5):1118-1130. 487 10. Jain A, Pandey N, Garg R, Kumar R. IL-17 level in patients with Dengue virus infection & 488 its association with severity of illness. Journal of clinical immunology. 2013;33(3):613-489 618. 490 11. Yuan J, Yu M, Lin Q-W, et al. Neutralization of IL-17 inhibits the production of anti-ANT 491 autoantibodies in CVB3-induced acute viral myocarditis. International 492 immunopharmacology. 2010;10(3):272-276. 493 12. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17–induced pulmonary pathogenesis during 494 respiratory viral infection and exacerbation of allergic disease. The American journal of 495 pathology. 2011;179(1):248-258. 13. 496 Du W-J, Zhen J-H, Zeng Z-Q, et al. Expression of interleukin-17 associated with disease 497 progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. 498 Diagnostic pathology. 2013;8(1):40. 499 14. Li C, Yang P, Sun Y, et al. IL-17 response mediates acute lung injury induced by the 2009 500 pandemic influenza A (H1N1) virus. Cell research. 2012;22(3):528-538. 501 Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ 15. 502 lymphocytes is associated with mucosal damage in SIV infection. Mucosal immunology. 503 2012;5(6):646-657. 504 16. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain, behavior, 505 and immunity. 2020. 506 17. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and 507 pathology. European journal of immunology. 2017;47(4):607-614. 508 18. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nature Reviews 509 Immunology. 2020;20(6):345-346. 510 Cooper JR, Pincus JH. The role of thiamine in nervous tissue. *Neurochemical research*. 19. 511 1979;4(2):223-239. 512 Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. 20. 513 *Current diabetes reviews.* 2005;1(3):287-298. 514 Neri M, Cantatore S, Pomara C, et al. Immunohistochemical expression of 21. 515 proinflammatory cytokines IL-1 β , IL-6, TNF- α and involvement of COX-2, quantitatively 516 confirmed by Western blot analysis, in Wernicke's encephalopathy. Pathology-Research 517 and Practice. 2011;207(10):652-658. 518 22. de Andrade JAA, Gaver CRM, de Almeida Nogueira NP, et al. The effect of thiamine 519 deficiency on inflammation, oxidative stress and cellular migration in an experimental 520 model of sepsis. Journal of Inflammation. 2014;11(1):11. 521 Menezes RR, Godin AM, Rodrigues FF, et al. Thiamine and riboflavin inhibit production 23. 522 of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic 523 model of inflammation induced by complete Freund's adjuvant. Pharmacological 524 Reports. 2017;69(5):1036-1043.

525 526	24.	Shahmiri FA, Soares M, Zhao Y, Sherriff J. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over
527		trial. European journal of nutrition. 2013;52(7):1821-1824.
528	25.	Protheroe S, Mellor D. Imaging in influenza A encephalitis. Archives of disease in
529		childhood. 1991;66(6):702-705.
530	26.	Brechtelsbauer D, Urbach H, Sommer T, Blümcke I, Woitas R, Solymosi L.
531 532		Cytomegalovirus encephalitis and primary cerebral lymphoma mimicking Wernicke's encephalopathy. <i>Neuroradiology</i> , 1997;39(1):19-22
532	27	Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the
534	27.	development of the Wernicke-Korsakoff syndrome. Alcohol and Alcoholism
534		2000-35(Supplement 1)-2-1
536	28	Vatsalva V Song M Schwandt ML et al Effects of sex drinking history and omega-3
530	20.	and omega-6 fatty acids dysregulation on the onset of liver injury in very heavy drinking
538		alcohol-dependent nations. Alcoholism: Clinical and Experimental Research
530		
540	29	Vatsalva V Kong M Cave MC et al. Association of serum zinc with markers of liver
540 541	23.	injury in very beavy drinking alcohol-dependent natients. The Journal of nutritional
541 542		hiochemistry 2018:59:49-55
543	30	Vatsalva V. Agrawal R. Frimodig I. Srivastava S. Schwandt MI. Dysregulation in Plasma
544	50.	(1)3 Fatty Acids Concentration and Serum Zinc in Heavy Alcohol-Drinking HCV Patients
545		Advances in Virology 2020:2020
546	31.	Vatsalva V. Cave MC. Kong M. et al. Keratin 18 is a diagnostic and prognostic factor for
547	01.	acute alcoholic hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019.
548	32.	Smithline HA. Donnino M. Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine
549		hydrochloride in healthy subjects. <i>BMC clinical pharmacology</i> . 2012;12(1):4.
550	33.	Mandel H, Berant M, Hazani A, Naveh Y. Thiamine-dependent beriberi in the thiamine-
551		responsive anemia syndrome. <i>New England Journal of Medicine</i> . 1984;311(13):836-838.
552	34.	Riaz S, Skinner V, Srai SK. Effect of high dose thiamine on the levels of urinary protein
553		biomarkers in diabetes mellitus type 2. Journal of pharmaceutical and biomedical
554		analysis. 2011;54(4):817-825.
555	35.	Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine
556		as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized,
557		Double-Blind, Placebo-controlled Trial. Ann Am Thorac Soc. 2017;14(5):737-741.
558	36.	Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and
559		thiamine for the treatment of severe sepsis and septic shock: a retrospective before-
560		after study. Chest. 2017;151(6):1229-1238.
561	37.	Mouly S. Beri-Beri and thiamine deficiency in HIV infection. <i>Aids.</i> 1996;10(8):931.
562	38.	Arici C, Tebaldi A, Quinzan G, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis
563		and thiamine administration in an HIV-infected patient on HAART. International journal
564		of STD & AIDS. 2001;12(6):407-409.
565	39.	Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV
566		medications. Journal of Medical Toxicology. 2014;10(1):26-39.

567	40.	Di Rocco M, Lamba LD, Minniti G, Caruso U, Naito E. Outcome of thiamine treatment in
508		a child with Leigh disease due to thannne-responsive pyruvate denydrogenase
509	4.1	deficiency. European Journal of Paealatric Neurology. 2000;4(3):115-117.
570	41.	Day E, Bentham PW, Callagnan R, Kuruvilla T, George S. Thiamine for prevention and
5/1		treatment of wernicke-korsakoff Syndrome in people who abuse alconol. <i>Cochrane</i>
572		Database of Systematic Reviews. 2013(7).
5/3	42.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
574		coronavirus in Wuhan, China. <i>The lancet.</i> 2020;395(10223):497-506.
575	43.	Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of
576		JAK2 Inhibitor Fedratinib. Journal of Microbiology, Immunology and Infection. 2020.
577	44.	Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective cytokines in COVID-19
578		patients reflect viral load and lung injury. <i>National Science Review</i> . 2020.
579	45.	Pirowska M, Obtułowicz A, Lipko-Godlewska S, Goździalska A, Podolec K, Wojas-Pelc A.
580		The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis
581		factor α in patients with metabolic syndrome accompanying severe psoriasis and
582		psoriatic arthritis. Advances in Dermatology and Allergology/Postępy Dermatologii i
583		Alergologii. 2018;35(4):360.
584	46.	Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with
585		rheumatoid arthritis is a potent stimulator of osteoclastogenesis. The Journal of clinical
586		investigation. 1999;103(9):1345-1352.
587	47.	Brunialti MKC, Santos MC, Rigato O, Machado FR, Silva E, Salomao R. Increased
588		percentages of T helper cells producing IL-17 and monocytes expressing markers of
589		alternative activation in patients with sepsis. <i>PloS one</i> . 2012;7(5):e37393.
590	48.	Li J, Li M, Su L, et al. Alterations of T helper lymphocyte subpopulations in sepsis, severe
591		sepsis, and septic shock: a prospective observational study. Inflammation.
592		2015;38(3):995-1002.
593	49.	Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of
594		influenza infection. The Journal of Immunology. 2009;183(8):5301-5310.
595	50.	Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22,
596		and IL-23, in inflammatory diseases. Clinical and Developmental Immunology.
597		2013;2013.
598	51.	Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with
599		COVID-19 in Wuhan, China: a retrospective case series study. 2020.
600	52.	Hotez PJ, Bottazzi ME, Corry DB. The potential role of TH17 immune responses in
601		coronavirus immunopathology and vaccine-induced immune enhancement. In: Elsevier;
602		2020.
603	53.	Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of
604		inflammatory diseases. Cell Signal. 2013;25(12):2335-2347.
605	54.	Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol.
606		2017;18(6):612-621.
607	55.	Lasiglie D, Traggiai E, Federici S, et al. Role of IL-1 Beta in the Development of Human TH
608		17 Cells: Lesson from NLPR3 Mutated Patients. PloS one. 2011;6(5):e20014.
609	56.	Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by
610		macrophages and T cells. European journal of immunology. 2008;38(7):1807-1813.

611 612 613	57.	Ji Z, Fan Z, Zhang Y, et al. Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. <i>The Journal of Immunology</i> . 2014;192(5):2157-2167
614	50	Z014,155(5).2157-2107. Mobratu VA Tosfaigzi VII. 17 Plays a Polo in Pospiratory Syncytial Virus induced Lung
615	58.	Inflammation and Emphysions in Elastase and LDS injured Mice. Am L Posnir Coll Mol
616		Riol 2018:58(6):717-726
617	50	Murdock BL Falkowski NP. Shrainar AB. at al. Interloukin 17 drives nulmenary
610	55.	accinential following repeated exposure to Aspergillus furnigatus conidia. Infection and
619		immunity. 2012;80(4):1424-1436.
620	60.	Shoji S, Furuishi K, Misumi S, Miyazaki T, Kino M, Yamataka K. Thiamine disulfide as a
621		potent inhibitor of human immunodeficiency virus (type-1) production. Biochemical and
622		biophysical research communications. 1994;205(1):967-975.
623	61.	Butterworth RF, Gaudreau C, Vincelette J, Bourgault A-M, Lamothe F, Nutini A-M.
624		Thiamine deficiency and Wernicke's encephalopathy in AIDS. <i>Metabolic brain disease.</i>
625		1991;6(4):207-212.
626	62.	Wallace AE, Weeks WB. Thiamine treatment of chronic hepatitis B infection. The
627		American journal of gastroenterology. 2001;96(3):864-868.
628	63.	Kim W-Y, Jo E-J, Eom JS, et al. Combined vitamin C, hydrocortisone, and thiamine
629		therapy for patients with severe pneumonia who were admitted to the intensive care
630		unit: Propensity score-based analysis of a before-after cohort study. Journal of critical
631		care. 2018;47:211-218.
632	64.	Coates PM, Betz JM, Blackman MR, et al. Encyclopedia of dietary supplements. CRC
633		Press; 2010.
634	65.	Boldorini R, Vago L, Lechi A, Tedeschi F, Trabattoni G. Wernicke's encephalopathy:
635		occurrence and pathological aspects in a series of 400 AIDS patients. Acta Bio-medica de
636		L'ateneo Parmense: Organo Della Societa di Medicina e Scienze Naturali di Parma.
637		1992;63(1-2):43-49.
638	66.	Larsen TR, Dragu D, Williams M. Wernicke's encephalopathy: an unusual consequence
639		of the acquired immune deficiency syndrome—case report and literature review. Case
640		reports in medicine. 2013;2013.
641	67.	Mendoza R, Anderson MM, Overbaugh J. A putative thiamine transport protein is a
642		receptor for feline leukemia virus subgroup A. Journal of Virology. 2006;80(7):3378-
643		3385.
644	68.	Plaut G. Water-soluble vitamins, part II (folic acid, riboflavin, thiamine, vitamin B12).
645		Annual Review of Biochemistry. 1961;30(1):409-444.
646	69.	Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W. Potential neurological symptoms
647		of COVID-19. Therapeutic Advances in Neurological Disorders.
648		2020;13:1756286420917830.
649	70.	Chaudhuri A, Kennedy P. Diagnosis and treatment of viral encephalitis. Postgraduate
650		medical journal. 2002;78(924):575-583.
651	71.	Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances
652		in diagnosis and management. The Lancet Neurology. 2007;6(5):442-455.
653	72.	Reuler JB, Girard DE, Cooney TG. Wernicke's encephalopathy. New England Journal of
654		Medicine. 1985;312(16):1035-1039.

655 656 657	73.	Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. <i>JAMA ophthalmology.</i> 2020:138(5):575-578
658	74	Lantos I. Strauss S. Lin F. COVID-19–Associated Miller Fisher Syndrome: MRI Findings
659	,	American Journal of Neuroradiology 2020
660	75	Keane IR Bilateral ocular paralysis: analysis of 31 inpatients. Archives of neurology
661	, 5.	2007;64(2):178-180.
662 663	76.	Keane JR. Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. <i>Archives</i> of neurology, 2005:62(5):714-717.
664	77.	Hedges III TR. Ophthalmoplegia associated with AIDS. Survey of ophthalmology.
665		1994;39(1):43-51.
666	78.	Sanjay S, Chan EWe, Gopal L, Hegde SR, Chang BC-M. Complete unilateral
667		ophthalmoplegia in herpes zoster ophthalmicus. Journal of Neuro-ophthalmology.
668		2009;29(4):325-337.
669	79.	Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the
670		central nervous system of a child with acute disseminated encephalomyelitis. <i>Pediatrics</i> .
671		2004;113(1):e73-e76.
672	80.	Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens.
673		The Lancet. 2002;359(9305):507-513.
674	81.	Kabakus N, Gurgoze MK, Yildirim H, Godekmerdan A, Aydın M. Acute hemorrhagic
675		leukoencephalitis manifesting as intracerebral hemorrhage associated with herpes
676		simplex virus type I. Journal of tropical pediatrics. 2005;51(4):245-249.
677	82.	Kumar G, Kalita J, Misra UK. Raised intracranial pressure in acute viral encephalitis.
678		Clinical neurology and neurosurgery. 2009;111(5):399-406.
679	83.	Hao X, Zhou D, Li Z, et al. Severe psychological distress among patients with epilepsy
680		during the COVID-19 outbreak in southwest China. Epilepsia. 2020.
681	84.	Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. Epilepsia. 2008;49:13-18.
682	85.	AGUILAR MJ, RASMUSSEN T. Role of encephalitis in pathogenesis of epilepsy. AMA
683		Archives of Neurology. 1960;2(6):663-676.
684	86.	Nguyen TA, Lam SW. Phenobarbital and symptom-triggered lorazepam versus
685		lorazepam alone for severe alcohol withdrawal in the intensive care unit. Alcohol.
686		2020;82:23-27.
687	87.	Steardo L, Steardo Jr L, Zorec R, Verkhratsky A. Neuroinfection may contribute to
688		pathophysiology and clinical manifestations of COVID-19. Acta Physiologica.
689		2020:e13473.
690	88.	Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF.
691		Neuropathology of COVID-19: a spectrum of vascular and acute disseminated
692		encephalomyelitis (ADEM)-like pathology. Acta Neuropathologica. 2020:1-6.
693	89.	Dale RC. Acute disseminated encephalomyelitis. Paper presented at: Seminars in
694		pediatric infectious diseases2003.
695	90.	Whitley RJ. Viral encephalitis. New England Journal of Medicine. 1990;323(4):242-250.
696	91.	Rao R, Topiwala A. Alcohol use disorders and the brain. Addiction. 2020.
697	92.	Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. Obesity.
698		2020;28(5):848-848.

699 700	93.	Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-
701 702		2020:1-11.
703	94.	Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected
704		patients. Journal of Medical Virology. 2020.
705	95.	Henkin R, Larson A, Powell R. Hypogeusia, dysgeusia, hyposmia, and dysosmia following
706 707		influenza-like infection. <i>Annals of Otology, Rhinology & Laryngology</i> . 1975;84(5):672-682.
708	96.	Bénézit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the
709		diagnosis of COVID-19. The Lancet Infectious Diseases. 2020.
710	97.	Azhideh A. COVID-19 Neurological Manifestations. International Clinical Neuroscience
711		Journal. 2020;7(2):54.
712	98.	Tang H, Falcone F, Eljamel S. Herpes simplex encephalitis following microvascular
713		decompression for trigeminal neuralgia: Case report. Journal of Neurosurgery.
714		2013;118(3):530-533.
715	99.	Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact
716		of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC medicine.
717		2010;8(1):37.
718	100.	Rose AS, Jacobson BM. Treatment of trigeminal neuralgia with vitamin B1 (thiamine
719		hydrochloride). Archives of Neurology & Psychiatry. 1940;44(6):1307-1311.
720	101.	Eckert M, Schejbal P. Therapy of neuropathies with a vitamin B combination.
721		Symptomatic treatment of painful diseases of the peripheral nervous system with a
722		combination preparation of thiamine, pyridoxine and cyanocobalamin. Fortschritte der
723		Medizin. 1992;110(29):544-548.
724	102.	He J, Wu B, Chen Y, et al. Characteristic ECG manifestations in patients with COVID-19.
725		Canadian Journal of Cardiology. 2020.
726	103.	Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic
727		complications in patients with COVID-19. Journal of Cardiovascular Electrophysiology.
728		2020;31(5):1003-1008.
729	104.	Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-
730		farmers in Malaysia. The Lancet. 1999;354(9186):1257-1259.
731	105.	Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and
732		treatment coronavirus (COVID-19). In: Statpearls [internet]. StatPearls Publishing; 2020.
733	106.	Ripamonti E, Gaffuri M, Molteni F. Cognitive, neuropsychiatric, and motor profile in post
734		tick-borne flaviviral encephalomyelitis. Neurological Sciences. 2020.
735	107.	Pitel A-L, Zahr NM, Jackson K, et al. Signs of preclinical Wernicke's encephalopathy and
736		thiamine levels as predictors of neuropsychological deficits in alcoholism without
737		Korsakott's syndrome. <i>Neuropsychopharmacology</i> . 2011;36(3):580-588.
738	108.	Nardone R, Bergmann J, Kronbichler M, et al. Altered motor cortex excitability to
739		magnetic stimulation in alcohol withdrawal syndrome. <i>Alcoholism: clinical and</i>
740		experimental research. 2010;34(4):628-632.

- 741 109. Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with
- 742 Wernicke-Korsakoff syndrome. *New England Journal of Medicine*. 1977;297(25):1367-743 1370.
- Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of
 Miller Fisher syndrome. *Neurology*. 2001;56(8):1104-1106.

746

Fig. 1a 0.201 100₁ *** *** (Jm/bd) 0.10 0.10 0.05 80 IL-22 (pg/ml) 60 **40** 20 Below Detection Range 0.00 0 IL-22 in HV BL IL-22 in DCW3 IL-22 in DC BL IL-17 in DC W3 IL-17 in DC IL-17 in HV

Fig. 1b







Fig. 4a

Fig. 4b

